MAPT and Alzheimer disease: In conclusion, these recent studies provide convincing evidence that p-tau biomarkers correlate with synaptic tau accumulation and cognitive decline in both Alzheimer’s disease and non-demented cohorts, further suggesting that targeting synaptic tau pathology could be a relevant therapeutic strategy for preventing cognitive decline in Alzheimer’s disease and aging.